At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 57 enrolled
Drug / intervention
RN6G +1 morebiological
Likely dose
RN6G 0.3mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Double-masked, Placebo-controlled Study Evaluating The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Immunogenicity Of Single Escalating Doses Of Rn6g In Patients With Dry, Age-related Macular Degeneration (Amd)
In Brief
A Phase 1 clinical trial evaluating RN6G and Placebo for Age-Related Maculopathy and 4 related conditions. Completed, enrolled 57 participants across 20 sites.
Detailed Summary
The purpose of this study is to determine the safety and tolerability of RN6G in patients with dry, age-related macular degeneration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedApr 2009
Primary CompletionJul 2011
TodayJul 2026
First PostedApr 7, 2009
Enrollment StartApr 1, 2009
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.2 years ago
Interventions
RN6Gbiological
intravenous, single dose, dose ranging from 0.3mg/kg up to a maximum of 40 mg/kg.
Placebobiological
intravenous, single dose with experimental dose.